Kiniksa Pharmaceuticals International (KNSA) Cash from Investing Activities (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Cash from Investing Activities for 10 years, with the latest figure at -$31.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 38.08% year-over-year to -$31.9 million; the trailing twelve-month figure through Mar 2026 stood at -$169.4 million (down 329.94% YoY), and the FY2025 full-year result was -$189.0 million, down 601.68% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$31.9 million, up from -$70.8 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $65.3 million in Q4 2024, with the low at -$70.8 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$13.0 million across 5 years, with a median of -$14.9 million in 2023.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities jumped 538.38% — and 2025, when it sank 888.58%.
• Kiniksa Pharmaceuticals International's Cash from Investing Activities stood at -$42.7 million in 2022, then jumped by 65.09% to -$14.9 million in 2023, then jumped by 538.38% to $65.3 million in 2024, then slumped by 208.46% to -$70.8 million in 2025, then jumped by 54.93% to -$31.9 million in 2026.
• The last three Cash from Investing Activities figures came in at -$31.9 million (Q1 2026), -$70.8 million (Q4 2025), and -$62.8 million (Q3 2025), per Business Quant data.